Quest Laboratories Limited

About the company

## **About  Quest Laboratories Limited** Incorporated in June 1998, Quest Laboratories Limited is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. The company produces a variety of products, comprising ethical drugs, generic drugs, and over the counter drugs (OTC). These products are available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids. The company possesses Good Laboratory Practice (GLP) certificate issued by Food & Drug Administration, Bhopal, Madhya Pradesh, indicating its commitment to maintaining high standards of quality and compliance in laboratory operations, particularly within the pharmaceutical sector. Their  in-house laboratory is equipped with various equipment such as HPLC (High-Performance Liquid Chromatography), GC (Gas Chromatography), FTIR (Fourier Transform Infrared Spectroscopy), UV (Ultraviolet-Visible Spectroscopy), Dissolution apparatus, and other advanced instruments. This comprehensive suite of tools enables us to conduct a wide array of tests and analyses efficiently and accurately. Their manufacturing facility is located at Pithampur Industrial Area, in Madhya Pradesh, India. The total area of the facility is approximately 4,065 square metres. Their manufacturing facilities are well equipped with the required facilities including machinery, other handling equipments to facilitate smooth manufacturing process and easy logistics. The company has been receiving sales orders from the private sector & government institutions on a regular basis. The company operates in the domestic market across 12 states and 2 union territories namely Uttar Pradesh, Madhya Pradesh, Maharashtra, Delhi, Jharkhand, Assam, Karnataka, Jammu & Kashmir, Rajasthan, West Bengal Gujarat, Telangana, Haryana and Bihar. Their  product mix has evolved over the past several years as they entered new product categories. They are consistently expanding their product portfolio through research and development of new pharmaceutical formulations. This comprehensive approach allows them to address a wide range of medical needs and preferences among patients.This process ensures that they create and maintain quality pharmaceutical products, meeting regulatory standards and satisfying customer expectations.With manufacturing under one roof,they maintain stringent quality control standards throughout the entire manufacturing process. By doing so, they ensure that their products meet the relevant quality standards before it hits the market.They endeavour to maintain safety in their premises by adhering to key safety norms, established through their internal health and safety manual, accompanied by regular safety meetings. Quest Laboratories Limited Prepares for its Initial Public Offering (IPO), the proceeds generated from the Fresh Issue will be allocated towards crucial objectives: 1. Funding of capital expenditure towards purchase of Plant and Machineries for Expansion and Upgradation at the existing Manufacturing Facility situated at Dhar, Madhya Pradesh 1. Funding Working Capital Requirements of our Company 1.  General corporate purposes Here are key details about the Quest Laboratories Limited IPO: Company Name| **Quest Laboratories Limited**|  | Quest Laboratories Limited IPO Opening Date| **May 15, 2024** ---|---|---|---|--- Company Established On|**1998**Quest Laboratories Limited IPO Price band|**₹93 to ₹97 per share**

Financial performance (₹ Cr)

IPO Roadmap / Timeline

1. IPO Opens

   Completed
   15 May 2024

   Bidding starts for all investor categories

2. IPO Closes

   Completed
   17 May 2024

   Last day to place your bid

3. Basis of Allotment

   Completed
   17 May 2024

   Share allotment finalised

4. Refund Initiation

   Completed
   22 May 2024

   Refunds credited for non-allottees

5. Credit to Demat

   Completed
   21 May 2024

   Allotted shares credited to demat account

6. Listing on Exchange

   Completed
   23 May 2024

   Shares list on NSE / BSE

Post-close dates are indicative as per SEBI T+3 listing framework and may change per registrar updates.